Compare Microsoft (MSFT) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Microsoft vs Vertex Pharmaceuticals Incorporated — how do they compare? Microsoft trades at $535.07 (market cap $3.88T), while Vertex Pharmaceuticals Incorporated trades at $509.5 (market cap $127.55B). The key difference: Microsoft is far larger — about 30.4× Vertex Pharmaceuticals Incorporated's market cap, and Microsoft pays a 0.75% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals — on Pluang, investors hold Microsoft for 142 Days and Vertex Pharmaceuticals Incorporated for 120 Days on average.
| MSFT | VRTX | |
|---|---|---|
Market Cap | $3.88T | $127.55B |
Volume | 19,593,392 | 1,487,944 |
Sector | Technology | Health |
52-Week High | $542.07 | $557.96 |
52-Week Low | $352.83 | $407.37 |
Typical Hold Time | 142 Days | 120 Days |
Enterprise Value | $3.86T | $121.68B |
Dividend Yield | 0.75% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Microsoft (MSFT) trades at $535.07, up 1.0% with strong bullish technical signals and consistent earnings beats. The company demonstrates robust fundamentals with 36.1% net margins, $281.7B revenue, and healthy cash flow generation. Recent analyst coverage shows 82% buy ratings with a $571.76 consensus target, while technical indicators suggest support at $517 and resistance at $530.
MSFT presents a compelling investment case with strong AI positioning and cloud growth, though elevated valuation metrics and competitive pressures warrant caution. The stock's current level near resistance suggests potential for consolidation before further upside, supported by institutional confidence and solid financial performance.
Vertex Pharmaceuticals (VRTX) trades at $510.08, up 0.88% with mixed technical signals showing bearish moving averages but neutral oscillators. The company reported strong 2025 results with $12B revenue and $4B net income, though recent quarterly earnings show inconsistent performance against expectations. Positive Phase 2b data for inaxaplin in kidney disease highlights pipeline progress beyond cystic fibrosis dominance.
Wall Street maintains strong bullish sentiment with 84% buy ratings and $573.50 consensus target, but risks include competitive pressures and reliance on CF franchise. The stock's premium valuation (P/E 29.31) requires continued execution on pipeline expansion to justify upside potential amid technical resistance near $515.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Microsoft
Microsoft Corporation develops, manufactures, licenses, sells, and supports software products. The Company offers operating system software, server application software, business and consumer applications software, software development tools, and Internet and intranet software. Microsoft also develops video game consoles and digital music entertainment devices.
Read more on MSFT →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
